Sandoz Gains An Edge With High-Concentration US Humira Biosimilar
Hyrimoz Version Of Adalimumab Approved By FDA In Citrate-Free 100mg/ml Form
Executive Summary
Sandoz has gained a potential advantage ahead of being part of a second wave of Humira biosimilar competition hitting the US, with the firm obtaining FDA approval for its Hyrimoz version of adalimumab in a citrate-free high-concentration formulation.
You may also be interested in...
Celltrion Bags FDA Approval For High-Concentration Humira Rival
Celltrion has won US FDA approval for its Yuflyma 100mg/ml adalimumab biosimilar, making it the third high-concentration version approved in the US and the ninth Humira rival overall.
What’s Next? Five Things To Look Out For In May
Generics Bulletin previews the most notable and anticipated events for May 2023.
Novartis Hikes Sandoz Sales Guide As Separation Edges Closer
Novartis reported 8% top-line growth for its Sandoz unit during the first quarter of 2023, one of the last before it is separated into a standalone company.